Digital therapeutics (DTx) – a fast-developing group of evidence-based therapeutic interventions driven by high-quality software products – is a major advancement in the field of Digital Health. Experts believe DTx demonstrates curative potential for a broad range of physical, mental and behavioral disorders.
DTx has experienced rapid growth over the past few years and the commercialization of DTx-related applications are primed to become major disrupters over the next decade. Furthermore, its enhanced reach – in terms of therapeutic use and market penetration – gives DTx a crucial advantage in improving patients’ health, addressing social determinants of health and achieving health equity.
In this article, we describe how DTx is becoming an integral cog of digital innovation in drug development, highlighting key aspects and prognosticating outcomes.
Integrating this novel approach into healthcare systems will become a necessity. And regulators, payers and health providers can expect to witness a paradigm shift in their approaches. We also expect progress in the areas of regulation, health technology assessment and reimbursement pathways to accommodate the value proposition of DTx in mainstream healthcare.
Join the conversation